131
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          <p class="first" id="d5234468e221">The combination of atezolizumab and bevacizumab showed encouraging antitumor activity and safety in a phase 1b trial involving patients with unresectable hepatocellular carcinoma. </p>

          Related collections

          Author and article information

          Journal
          New England Journal of Medicine
          N Engl J Med
          Massachusetts Medical Society
          0028-4793
          1533-4406
          May 14 2020
          May 14 2020
          : 382
          : 20
          : 1894-1905
          Affiliations
          [1 ]From the Jonsson Comprehensive Cancer Center, Geffen School of Medicine at UCLA, Los Angeles (R.S.F.), the City of Hope Comprehensive Cancer Center and Beckman Research Institute, Duarte (D.L.), and Genentech, South San Francisco (W.V., S.H., Y.W.) — all in California; the People’s Liberation Army Cancer Center, Jinling Hospital, Nanjing (S.Q.), and Roche Product Development (D.-Z.X., J.L., C.H.) and Jiahui International Cancer Center, Jiahui Health (A.X.Z.), Shanghai — all in China; National Cancer...
          Article
          10.1056/NEJMoa1915745
          32402160
          e34fd663-fc89-477d-a626-fd1ede012eac
          © 2020

          http://www.nejmgroup.org/legal/terms-of-use.htm

          History

          Comments

          Comment on this article